| Effective treatment of female androgenic alopecia with dutasteride. | |
| | |
MedLine Citation:
|
PMID: 16167423 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dihydrotestosterone is the main molecule responsible for androgenic alopecia. Finasteride, which reduces transformation of testosterone into dihydrotestosterone and decreases dihydrotestosterone activity, is approved for treatment of androgenic alopecia in men. We describe the case of a 46-year-old woman with androgenic alopecia, non-responsive to minoxidil, who initially benefited from finasteride. Due to only limited improvement after finasteride and persisting profound psychological distress resulting from androgenic alopecia, another 5-reductase inhibitor, dutasteride, was introduced. Clinical evaluation and trichogram were applied for assessment of dutasteride efficacy in this patient. Additionally, mean hair diameter was monitored by means of computer dermoscopy. After 6 months of therapy, significant improvement was observed and after 9 months the clinical diagnosis of androgenic alopecia could no longer be made in this patient. No side effects were observed. In conclusion, theoretical data and our experience in this case show that dutasteride might develop into a true alternative in treatment of androgenic alopecia. |
| | |
Authors:
|
Malgorzata Olszewska; Lidia Rudnicka |
Related Documents
:
|
12656943 - Ziprasidone-associated mania: a case series and review of the mechanism. 2128853 - Adverse events reported in association with the use of monoclonal antibody purified fac... 20129513 - Anatomical landmark asymmetry assessment in the lumbar spine and pelvis: a review of re... |
Publication Detail:
|
Type: Case Reports; Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 4 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2005 Sep-Oct |
Date Detail:
|
Created Date: 2005-09-19 Completed Date: 2005-10-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 637-40 Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Warsaw Medical School, Warsaw, Poland. malgorzataolszewska@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alopecia
/
drug therapy*,
pathology Azasteroids / adverse effects, therapeutic use* Enzyme Inhibitors / adverse effects, therapeutic use* Female Finasteride / therapeutic use Humans Middle Aged Minoxidil / therapeutic use Scalp / pathology Skin / pathology Testosterone 5-alpha-Reductase / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Azasteroids; 0/Enzyme Inhibitors; 0/dutasteride; 38304-91-5/Minoxidil; 98319-26-7/Finasteride; EC 1.3.99.5/Testosterone 5-alpha-Reductase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Punctate palmoplantar keratoderma (Buschke-Fischer-Brauer disease) with psoriasis: a rare associatio...
Next Document: Cutaneous leiomyomatosis and parotid pleomorphic adenoma.